Therapeutic rescue of Polycystin-1 protein expression by targeting PKD1 upstream open reading frames
通过靶向 PKD1 上游开放阅读框来治疗性挽救 Polycystin-1 蛋白表达
基本信息
- 批准号:10575251
- 负责人:
- 金额:$ 12.56万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-03-01 至 2025-02-28
- 项目状态:未结题
- 来源:
- 关键词:5&apos Untranslated RegionsAffectAllelesAntisense OligonucleotidesAutosomal Dominant Polycystic KidneyBacterial Artificial ChromosomesCell LineCell surfaceCellsClinicalClustered Regularly Interspaced Short Palindromic RepeatsCystCystic kidneyDataDiseaseEndoplasmic ReticulumEpitheliumEpitopesFDA approvedFundingGenesGenetic TranscriptionGenomicsGrowthHepatic CystHumanHuman Cell LineImpairmentIn VitroInitiator CodonInstitutionInterventionKidneyKidney FailureLifeLiquid substanceLiverLocationLuciferasesMessenger RNAModelingMusMutationOpen Reading FramesPKD1 genePKD2 genePKD2 proteinPRKCSH proteinPainPathogenicityPatientsPeptidesPersonsPhenotypeProductionProteinsPublishingRNARNA SequencesRenal tubule structureRenilla LuciferasesReporterRibosomesSeveritiesSeverity of illnessSiteStructureTestingTherapeuticTherapeutic InterventionTransfectionTranslatingTranslation InitiationTranslationsWestern BlottingWorkabdominal distensionbase editingdesigndosageeffective therapyfunctional lossgenome editinggenome-widein vivoin vivo Modelinterestmouse modelmutantnovel strategiespatient subsetspolycystic kidney disease 1 proteinpre-clinical therapypreclinical evaluationpreclinical studyprotein expressiontranslational potential
项目摘要
Project Summary/Abstract
Autosomal dominant polycystic kidney disease (ADPKD) affects over 12 million people worldwide. Available
therapies provide only a slight delay in ongoing growth of fluid-filled cysts in the kidney and liver that progress
to kidney failure and in some cases devastating pain and abdominal distension. Approximately one third of
ADPKD patients have non-truncating mutations in the primary disease gene PKD1/Polycystin-1(PC1). A
significant subset of these encode a version of PC1 that fails to mature to its site of action at the cell surface
yet may be an at least partially functional PC1 protein. PC1 “dosage”—the functional amount of PC1 protein at
its site of action—correlates with disease severity. Nonetheless, feasible approaches to increase PC1 dosage
had not previously been identified to evaluate therapeutically.
We have contributed to the identification and characterization of several disease genes that encode proteins in
the endoplasmic reticulum (ER) that are necessary for PC1 maturation. Patients with mutations in these genes
also get kidney and liver cyst due to insufficient PC1 dosage, and many are in desperate need of treatmentsIn
mouse models for these genes, increasing PC1 production by increasing a mouse’s genomic copy number of
Pkd1 provides a striking rescue of cyst formation. We hypothesize that increasing PC1 protein expression
in patients with mutations in these ER genes and in a substantial subset of patients with PKD1 non-
truncating mutations will dramatically reduce cyst burden.
We have identified, with supportive preliminary data, that the 5’ untranslated region of human PKD1 contains
likely highly relevant upstream open reading frames (uORFs). uORF translation distracts ribosomes away from
translating the intended protein. Our data suggests that blocking PKD1 uORF translation would produce a many-
fold increase in translation of PC1. Blocking uORF translation is achievable as a clinical therapy using antisense
oligonucleotides (ASO). ASOs are approved therapies for other diseases. For this proposal we will test and
characterize the effect of abolishing human PKD1 uORF translation to increase PC1 expression and
generate in vivo models for preclinical evaluation of this treatment on cystic disease severity. For our
first aim we will evaluate two independent approaches in vitro: (1) edit uORF initiation codon sequence in the
human PKD1 5’UTR using CRISPR to test the effect of uORF translation on PC1 expression, and (2) test and
optimize ASOs to characterize the effect of steric inhibition of uORF translation and RNA secondary structure
on PC1 expression. For aim 2 we will use CRISPR to humanize the 5’UTR of our epitope-tagged Pkd1-V5 mouse
with or without uORF initiation codon edits. We will test the benefit of abolished uORFs to have a clinically
meaningful effect on cyst formation and severity in our PC1 dosage-dependent mouse models and optimize
models to evaluate for preclinical therapies.
项目总结/摘要
常染色体显性遗传性多囊肾病(ADPKD)影响全球超过1200万人。可用
治疗仅稍微延迟了肾脏和肝脏中充满液体的囊肿的持续生长
导致肾衰竭,有时还会出现致命的疼痛和腹胀。大约三分之一
ADPKD患者在原发疾病基因PKD 1/多囊蛋白-1(PC 1)中存在非截短突变。一
其中一个重要的亚群编码一种不能成熟到细胞表面作用位点的PC 1
还可以是至少部分功能性的PC 1蛋白。PC 1“剂量”-在200 mg/kg时PC 1蛋白的功能量。
其作用部位与疾病严重程度相关。然而,增加PC 1剂量的可行方法
以前没有被确定用于治疗评估。
我们已经对几种编码蛋白质的疾病基因的鉴定和表征做出了贡献,
内质网(ER)是PC 1成熟所必需的。这些基因发生突变的患者
由于PC 1剂量不足,也会出现肾囊肿和肝囊肿,许多人迫切需要治疗。
这些基因的小鼠模型,通过增加小鼠的基因组拷贝数来增加PC 1的产量,
pkd 1提供了一个惊人的拯救囊肿形成。我们假设PC 1蛋白表达的增加
在这些ER基因突变的患者中,以及在PKD 1非
截短突变将显著降低囊肿负荷。
我们已经确定,与支持的初步数据,5'非翻译区的人PKD 1含有
可能高度相关的上游开放阅读框(uORF)。uORF翻译使核糖体远离
翻译目的蛋白质。我们的数据表明,阻断PKD 1 uORF翻译会产生许多-
PC 1的翻译倍数增加。阻断uORF翻译作为使用反义核酸的临床疗法是可实现的。
寡核苷酸(阿索)。ASO被批准用于治疗其他疾病。对于这个建议,我们将测试和
表征消除人PKD 1 uORF翻译以增加PC 1表达的作用,
生成体内模型,用于临床前评估这种治疗对囊性疾病严重程度的影响。为我们
第一个目的,我们将在体外评估两种独立的方法:(1)编辑uORF起始密码子序列,
使用CRISPR检测人PKD 1 5 'UTR,以测试uORF翻译对PC 1表达的影响,和(2)测试和
优化ASO以表征uORF翻译和RNA二级结构的空间抑制效应
PC 1表达。对于目标2,我们将使用CRISPR来人源化我们的表位标记的Pkd 1-V5小鼠的5 'UTR。
有或没有uORF起始密码子编辑。我们将测试废除的uORF的益处,
在我们的PC 1剂量依赖性小鼠模型中对囊肿形成和严重程度产生有意义的影响并优化
用于评估临床前治疗的模型。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Whitney Elise Besse其他文献
Whitney Elise Besse的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Whitney Elise Besse', 18)}}的其他基金
Molecular genetic bases of polycystic and tubulointerstitial kidney diseases
多囊肾和肾小管间质性肾病的分子遗传学基础
- 批准号:
10388290 - 财政年份:2019
- 资助金额:
$ 12.56万 - 项目类别:
Molecular genetic bases of polycystic and tubulointerstitial kidney diseases
多囊肾和肾小管间质性肾病的分子遗传学基础
- 批准号:
10132310 - 财政年份:2019
- 资助金额:
$ 12.56万 - 项目类别:
Molecular genetic bases of polycystic and tubulointerstitial kidney diseases
多囊肾和肾小管间质性肾病的分子遗传学基础
- 批准号:
10886998 - 财政年份:2019
- 资助金额:
$ 12.56万 - 项目类别:
Molecular genetic bases of polycystic and tubulointerstitial kidney diseases
多囊肾和肾小管间质性肾病的分子遗传学基础
- 批准号:
10597658 - 财政年份:2019
- 资助金额:
$ 12.56万 - 项目类别:
相似海外基金
Impact of alternative polyadenylation of 3'-untranslated regions in the PI3K/AKT cascade on microRNA
PI3K/AKT 级联中 3-非翻译区的替代多聚腺苷酸化对 microRNA 的影响
- 批准号:
573541-2022 - 财政年份:2022
- 资助金额:
$ 12.56万 - 项目类别:
University Undergraduate Student Research Awards
How do untranslated regions of cannabinoid receptor type 1 mRNA determine receptor subcellular localisation and function?
1 型大麻素受体 mRNA 的非翻译区如何决定受体亚细胞定位和功能?
- 批准号:
2744317 - 财政年份:2022
- 资助金额:
$ 12.56万 - 项目类别:
Studentship
MICA:Synthetic untranslated regions for direct delivery of therapeutic mRNAs
MICA:用于直接递送治疗性 mRNA 的合成非翻译区
- 批准号:
MR/V010948/1 - 财政年份:2021
- 资助金额:
$ 12.56万 - 项目类别:
Research Grant
Translational Control by 5'-untranslated regions
5-非翻译区域的翻译控制
- 批准号:
10019570 - 财政年份:2019
- 资助金额:
$ 12.56万 - 项目类别:
Translational Control by 5'-untranslated regions
5-非翻译区域的翻译控制
- 批准号:
10223370 - 财政年份:2019
- 资助金额:
$ 12.56万 - 项目类别:
Translational Control by 5'-untranslated regions
5-非翻译区域的翻译控制
- 批准号:
10455108 - 财政年份:2019
- 资助金额:
$ 12.56万 - 项目类别:
Synergistic microRNA-binding sites, and 3' untranslated regions: a dialogue of silence
协同的 microRNA 结合位点和 3 非翻译区:沉默的对话
- 批准号:
255762 - 财政年份:2012
- 资助金额:
$ 12.56万 - 项目类别:
Operating Grants
Analysis of long untranslated regions in Nipah virus genome
尼帕病毒基因组长非翻译区分析
- 批准号:
20790351 - 财政年份:2008
- 资助金额:
$ 12.56万 - 项目类别:
Grant-in-Aid for Young Scientists (B)
Search for mRNA elements involved in the compatibility between 5' untranslated regions and coding regions in chloroplast translation
寻找参与叶绿体翻译中 5 非翻译区和编码区之间兼容性的 mRNA 元件
- 批准号:
19370021 - 财政年份:2007
- 资助金额:
$ 12.56万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Post-transcriptional Regulation of PPAR-g Expression by 5'-Untranslated Regions
5-非翻译区对 PPAR-g 表达的转录后调控
- 批准号:
7131841 - 财政年份:2006
- 资助金额:
$ 12.56万 - 项目类别: